Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FKB327 Registry Study in Ulcerative Colitis, Crohn's Disease, and Psoriatic Arthritis
jRCT1031210582Active, not recruiting
- Sponsor
- Sandoz
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of qletli in autoimmune colitis, Crohn's disease and psoriatic arthritis (PsA) (2 arms), sponsored by Sandoz. Primary endpoints: Primary endpoint - clinical remission at 24 weeks in biologic-naive patients (UC and CD), Primary endpoint - functional remission at 24 weeks in biologic-naive psoriatic arthritis and 2 more. Started Jan 2022; status: active, not recruiting.
02
Drugs
qletli
03
Conditions
autoimmune colitisCrohn's diseasepsoriatic arthritis (PsA)
Beyond the preview
Go deeper on jRCT1031210582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031210582.